<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7600111</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5310</journal-id>
<journal-id journal-id-type="nlm-ta">J Neurosci Res</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Neurosci. Res.</journal-id>
<journal-title-group>
<journal-title>Journal of neuroscience research</journal-title>
</journal-title-group>
<issn pub-type="ppub">0360-4012</issn>
<issn pub-type="epub">1097-4547</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29704429</article-id>
<article-id pub-id-type="pmc">6766750</article-id>
<article-id pub-id-type="doi">10.1002/jnr.24250</article-id>
<article-id pub-id-type="manuscript">NIHMS1051233</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Understanding Vision Loss from Optic Pathway Glioma in Neurofibromatosis Type 1</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Freret</surname>
<given-names>Morgan E.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gutmann</surname>
<given-names>David H.</given-names>
</name>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<aff id="A1">Department of Neurology, Washington University School of Medicine, St. Louis, MO, 63110, USA</aff>
</contrib-group>
<author-notes>
<corresp id="CR1"><label>*</label>To whom correspondence should be addressed: Telephone:314-362-7379, Facsimile:314-362-2388, <email>gutmannd@wustl.edu</email></corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P33"><bold>Conflict of interest:</bold> The authors declare no conflicts of interest</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>19</day>
<month>9</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>28</day>
<month>4</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>30</day>
<month>9</month>
<year>2019</year>
</pub-date>
<volume>97</volume>
<issue>1</issue>
<fpage>45</fpage>
<lpage>56</lpage>
<!--elocation-id from pubmed: 10.1002/jnr.24250-->
<abstract id="ABS1">
<p id="P1">Neurofibromatosis type 1 (NF1) is a common cancer predisposition syndrome caused by mutations in the <italic>NF1</italic> gene. The <italic>NF1</italic>-encoded protein (neurofibromin) functions as an inhibitor of RAS to control cell growth and survival. Individuals with NF1 are prone to developing low-grade tumors of the optic nerves, chiasm, tracts, and radiations, termed optic pathway gliomas (OPGs), which can cause vision loss. A paucity of surgical tumor specimens and patient-derived xenografts for investigative studies has limited our understanding of human NF1-associated OPG (NF1-OPG). However, mice genetically engineered to harbor <italic>Nf1</italic> gene mutations develop optic gliomas that share many features of their human counterparts. These genetically engineered mouse (GEM) strains have provided important insights into the cellular and molecular determinants that underlie mouse <italic>Nf1</italic> optic glioma development, maintenance, and associated vision loss, with relevance to human NF1-OPG disease. Herein, we review our current understanding of NF1-OPG pathobiology and describe the mechanisms responsible for tumor initiation, growth, and associated vision loss in <italic>Nf1</italic> GEM models. We also discuss how <italic>Nf1</italic> GEM strains and other preclinical models can be deployed to identify and evaluate molecularly targeted therapies for OPG, particularly as they pertain to future strategies aimed at preventing or improving tumor-associated vision loss in children with NF1.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>